GlassScriptPhysician profile
Sanjay Chaudhry
NPI 1013088228
$5,288.98
in general payments reported to CMS, 2019-2025
29 companies · $89.40 in 2025
The $89.40 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $994 · 2021: $1,153 · 2022: $1,220 · 2023: $921 · 2024: $152 · 2025: $89.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122 · Gift: $40.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.66 |
| Gift | $40.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,299.89 | 2019-2024 | Linzess, Viberzi, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $760.24 | 2019-2025 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $750.38 | 2019-2024 | Stelara, Remicade, Simponi Aria |
| Braintree Laboratories, INC. | $423.22 | 2019-2023 | Sutab, Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $399.02 | 2019-2023 | Entyvio |
| Allergan, INC. | $182.48 | 2019-2020 | |
| Celgene Corporation | $158.66 | 2021-2023 | Zeposia |
| Redhill Biopharma INC. | $157.30 | 2020-2022 | |
| Boston Scientific Corporation | $114.54 | 2021 | |
| Ironwood Pharmaceuticals, INC | $105.63 | 2020 | |
| Flowonix Medical Incorporated | $98.27 | 2020 | |
| Merck Sharp & Dohme LLC | $95.48 | 2020-2023 | Dificid |
| Abbott Laboratories | $94.37 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $84.32 | 2022-2023 | Breztri |
| Edwards Lifesciences Corporation | $69.49 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $56.98 | 2022-2023 | Ibsrela |
| Madrigal Pharmaceuticals | $50.14 | 2025 | Rezdiffra |
| Novo Nordisk INC | $50.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.10 | 2019 | |
| Genzyme Corporation | $47.88 | 2022-2024 | |
| Daiichi Sankyo INC. | $46.14 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.56 | 2022 | |
| Alfasigma USA, INC. | $36.24 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $36.09 | 2024-2025 | Dupixent |
| Gilead Sciences, INC. | $29.97 | 2019-2020 | |
| Shionogi INC | $15.35 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.87 | 2022 | |
| Exact Sciences Corporation | $13.74 | 2024 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.